These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1043 related articles for article (PubMed ID: 26072097)
1. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097 [TBL] [Abstract][Full Text] [Related]
2. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005 [TBL] [Abstract][Full Text] [Related]
4. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G; Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059 [TBL] [Abstract][Full Text] [Related]
6. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Mavroudis D; Pavlakou G; Blazoyiannakis G; Veslemes M; Apostolopoulou F; Kouroussis Ch; Kakolyris S; Agelaki S; Androulakis N; Vardakis N; Magkanas E; Samonis G; Georgoulias V Lung Cancer; 2003 Jan; 39(1):71-6. PubMed ID: 12499097 [TBL] [Abstract][Full Text] [Related]
7. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556 [TBL] [Abstract][Full Text] [Related]
9. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T; Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V; Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794 [TBL] [Abstract][Full Text] [Related]
11. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. Schiller JH; Adak S; Cella D; DeVore RF; Johnson DH J Clin Oncol; 2001 Apr; 19(8):2114-22. PubMed ID: 11304763 [TBL] [Abstract][Full Text] [Related]
12. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768 [TBL] [Abstract][Full Text] [Related]
13. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. Baka S; Agelaki S; Kotsakis A; Veslemes M; Papakotoulas P; Agelidou M; Agelidou A; Tsaroucha E; Pavlakou G; Gerogianni A; Androulakis N; Vamvakas L; Kalbakis K; Mavroudis D; Georgoulias V Anticancer Res; 2010 Jul; 30(7):3031-8. PubMed ID: 20683051 [TBL] [Abstract][Full Text] [Related]
14. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. Petrioli R; Francini E; Fiaschi AI; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Bianco V; Roviello G Med Oncol; 2015 Apr; 32(4):134. PubMed ID: 25796503 [TBL] [Abstract][Full Text] [Related]
15. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010 [TBL] [Abstract][Full Text] [Related]
16. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149 [TBL] [Abstract][Full Text] [Related]
17. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. Horn L; Dahlberg SE; Sandler AB; Dowlati A; Moore DF; Murren JR; Schiller JH J Clin Oncol; 2009 Dec; 27(35):6006-11. PubMed ID: 19826110 [TBL] [Abstract][Full Text] [Related]
19. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study. Niho S; Ohe Y; Ohmatsu H; Umemura S; Matsumoto S; Yoh K; Goto K Lung Cancer; 2017 Jun; 108():66-71. PubMed ID: 28625650 [TBL] [Abstract][Full Text] [Related]
20. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial. Tiseo M; Boni L; Ambrosio F; Camerini A; Vitale MG; Baldini E; Cinieri S; Zanelli F; Defraia E; Passalacqua R; Crino L; Dazzi C; Tibaldi C; Turolla GM; D'Alessandro V; Zilembo N; Riccardi F; Ardizzoni A; Clin Lung Cancer; 2015 Jan; 16(1):67-70. PubMed ID: 25450879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]